Desmoplastic infantile ganglioglioma: A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor

Melissa M. Blessing, Patrick R. Blackburn, Chandra Krishnan, Virginia L. Harrod, Emily G.Barr Fritcher, Christopher D. Zysk, Rory A. Jackson, Dragana Milosevic, Asha A. Nair, Jaime I. Davila, Jessica R. Balcom, Robert B. Jenkins, Kevin C. Halling, Benjamin R. Kipp, Amulya A.Nageswara Rao, Nadia N. Laack, David J. Daniels, William R. Macon, Cristiane M. Ida

Research output: Contribution to journalArticle

Abstract

MAPK pathway activation has been recurrently observed in desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) with reported disproportionally low mutation allele frequencies relative to the apparent high tumor content, suggesting that MAPK pathway alterations may be subclonal. We sought to expand the number of molecularly profiled cases and investigate if tumor cell composition could account for the observed low mutation allele frequencies. Molecular (targeted neuro-oncology next-generation sequencing/RNA sequencing and OncoScan microarray) and immunohistochemical (CD68-PGM1/CD163/CD14/CD11c/lysozyme/CD3/CD20/CD34/ PD-L1) studies were performed in 7 DIG. Activating MAPK pathway alterations were identified in 4 (57%) cases: 3 had a BRAF mutation (V600E/V600D/V600-W604delinsDQTDG, at 8%-27% variant allele frequency) and 1 showed a TPM3-NRTK1 fusion. Copy number changes were infrequent and nonrecurrent. All tumors had at least 30% of cells morphologically and immunophenotypically consistent with microglial/macrophage lineage. Two subtotally resected tumors regrew; 1 was re-excised and received adjuvant treatment (chemotherapy/targeted therapy), with clinical response to targeted therapy only. Even with residual tumor, all patients are alive (median follow-up, 83 months; 19-139). This study further supports DIG as another MAPK pathway-driven neuroepithelial tumor, thus expanding potential treatment options for tumors not amenable to surgical cure, and suggests that DIG is a microglia/macrophage-rich neuroepithelial tumor with frequent low driver mutation allele frequencies.

Original languageEnglish (US)
Pages (from-to)1011-1021
Number of pages11
JournalJournal of Neuropathology and Experimental Neurology
Volume78
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Ganglioglioma
Neuroepithelial Neoplasms
Microglia
Gene Frequency
Macrophages
Mutation Rate
Neoplasms
RNA Sequence Analysis
Astrocytoma
Residual Neoplasm
Therapeutics
Adjuvant Chemotherapy
Muramidase
Mutation

Keywords

  • BRAF
  • Desmoplastic infantile ganglioglioma (DIG)
  • Glioma
  • Molecular
  • NTRK
  • Pediatric
  • TPM3

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Desmoplastic infantile ganglioglioma : A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor. / Blessing, Melissa M.; Blackburn, Patrick R.; Krishnan, Chandra; Harrod, Virginia L.; Fritcher, Emily G.Barr; Zysk, Christopher D.; Jackson, Rory A.; Milosevic, Dragana; Nair, Asha A.; Davila, Jaime I.; Balcom, Jessica R.; Jenkins, Robert B.; Halling, Kevin C.; Kipp, Benjamin R.; Rao, Amulya A.Nageswara; Laack, Nadia N.; Daniels, David J.; Macon, William R.; Ida, Cristiane M.

In: Journal of Neuropathology and Experimental Neurology, Vol. 78, No. 11, 01.11.2019, p. 1011-1021.

Research output: Contribution to journalArticle

Blessing, MM, Blackburn, PR, Krishnan, C, Harrod, VL, Fritcher, EGB, Zysk, CD, Jackson, RA, Milosevic, D, Nair, AA, Davila, JI, Balcom, JR, Jenkins, RB, Halling, KC, Kipp, BR, Rao, AAN, Laack, NN, Daniels, DJ, Macon, WR & Ida, CM 2019, 'Desmoplastic infantile ganglioglioma: A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor', Journal of Neuropathology and Experimental Neurology, vol. 78, no. 11, pp. 1011-1021. https://doi.org/10.1093/jnen/nlz086
Blessing, Melissa M. ; Blackburn, Patrick R. ; Krishnan, Chandra ; Harrod, Virginia L. ; Fritcher, Emily G.Barr ; Zysk, Christopher D. ; Jackson, Rory A. ; Milosevic, Dragana ; Nair, Asha A. ; Davila, Jaime I. ; Balcom, Jessica R. ; Jenkins, Robert B. ; Halling, Kevin C. ; Kipp, Benjamin R. ; Rao, Amulya A.Nageswara ; Laack, Nadia N. ; Daniels, David J. ; Macon, William R. ; Ida, Cristiane M. / Desmoplastic infantile ganglioglioma : A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor. In: Journal of Neuropathology and Experimental Neurology. 2019 ; Vol. 78, No. 11. pp. 1011-1021.
@article{c9235f7231e4448793d886c87ba2c7ad,
title = "Desmoplastic infantile ganglioglioma: A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor",
abstract = "MAPK pathway activation has been recurrently observed in desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) with reported disproportionally low mutation allele frequencies relative to the apparent high tumor content, suggesting that MAPK pathway alterations may be subclonal. We sought to expand the number of molecularly profiled cases and investigate if tumor cell composition could account for the observed low mutation allele frequencies. Molecular (targeted neuro-oncology next-generation sequencing/RNA sequencing and OncoScan microarray) and immunohistochemical (CD68-PGM1/CD163/CD14/CD11c/lysozyme/CD3/CD20/CD34/ PD-L1) studies were performed in 7 DIG. Activating MAPK pathway alterations were identified in 4 (57{\%}) cases: 3 had a BRAF mutation (V600E/V600D/V600-W604delinsDQTDG, at 8{\%}-27{\%} variant allele frequency) and 1 showed a TPM3-NRTK1 fusion. Copy number changes were infrequent and nonrecurrent. All tumors had at least 30{\%} of cells morphologically and immunophenotypically consistent with microglial/macrophage lineage. Two subtotally resected tumors regrew; 1 was re-excised and received adjuvant treatment (chemotherapy/targeted therapy), with clinical response to targeted therapy only. Even with residual tumor, all patients are alive (median follow-up, 83 months; 19-139). This study further supports DIG as another MAPK pathway-driven neuroepithelial tumor, thus expanding potential treatment options for tumors not amenable to surgical cure, and suggests that DIG is a microglia/macrophage-rich neuroepithelial tumor with frequent low driver mutation allele frequencies.",
keywords = "BRAF, Desmoplastic infantile ganglioglioma (DIG), Glioma, Molecular, NTRK, Pediatric, TPM3",
author = "Blessing, {Melissa M.} and Blackburn, {Patrick R.} and Chandra Krishnan and Harrod, {Virginia L.} and Fritcher, {Emily G.Barr} and Zysk, {Christopher D.} and Jackson, {Rory A.} and Dragana Milosevic and Nair, {Asha A.} and Davila, {Jaime I.} and Balcom, {Jessica R.} and Jenkins, {Robert B.} and Halling, {Kevin C.} and Kipp, {Benjamin R.} and Rao, {Amulya A.Nageswara} and Laack, {Nadia N.} and Daniels, {David J.} and Macon, {William R.} and Ida, {Cristiane M.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1093/jnen/nlz086",
language = "English (US)",
volume = "78",
pages = "1011--1021",
journal = "Journal of neuropathology and experimental neurology",
issn = "0022-3069",
number = "11",

}

TY - JOUR

T1 - Desmoplastic infantile ganglioglioma

T2 - A MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor

AU - Blessing, Melissa M.

AU - Blackburn, Patrick R.

AU - Krishnan, Chandra

AU - Harrod, Virginia L.

AU - Fritcher, Emily G.Barr

AU - Zysk, Christopher D.

AU - Jackson, Rory A.

AU - Milosevic, Dragana

AU - Nair, Asha A.

AU - Davila, Jaime I.

AU - Balcom, Jessica R.

AU - Jenkins, Robert B.

AU - Halling, Kevin C.

AU - Kipp, Benjamin R.

AU - Rao, Amulya A.Nageswara

AU - Laack, Nadia N.

AU - Daniels, David J.

AU - Macon, William R.

AU - Ida, Cristiane M.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - MAPK pathway activation has been recurrently observed in desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) with reported disproportionally low mutation allele frequencies relative to the apparent high tumor content, suggesting that MAPK pathway alterations may be subclonal. We sought to expand the number of molecularly profiled cases and investigate if tumor cell composition could account for the observed low mutation allele frequencies. Molecular (targeted neuro-oncology next-generation sequencing/RNA sequencing and OncoScan microarray) and immunohistochemical (CD68-PGM1/CD163/CD14/CD11c/lysozyme/CD3/CD20/CD34/ PD-L1) studies were performed in 7 DIG. Activating MAPK pathway alterations were identified in 4 (57%) cases: 3 had a BRAF mutation (V600E/V600D/V600-W604delinsDQTDG, at 8%-27% variant allele frequency) and 1 showed a TPM3-NRTK1 fusion. Copy number changes were infrequent and nonrecurrent. All tumors had at least 30% of cells morphologically and immunophenotypically consistent with microglial/macrophage lineage. Two subtotally resected tumors regrew; 1 was re-excised and received adjuvant treatment (chemotherapy/targeted therapy), with clinical response to targeted therapy only. Even with residual tumor, all patients are alive (median follow-up, 83 months; 19-139). This study further supports DIG as another MAPK pathway-driven neuroepithelial tumor, thus expanding potential treatment options for tumors not amenable to surgical cure, and suggests that DIG is a microglia/macrophage-rich neuroepithelial tumor with frequent low driver mutation allele frequencies.

AB - MAPK pathway activation has been recurrently observed in desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) with reported disproportionally low mutation allele frequencies relative to the apparent high tumor content, suggesting that MAPK pathway alterations may be subclonal. We sought to expand the number of molecularly profiled cases and investigate if tumor cell composition could account for the observed low mutation allele frequencies. Molecular (targeted neuro-oncology next-generation sequencing/RNA sequencing and OncoScan microarray) and immunohistochemical (CD68-PGM1/CD163/CD14/CD11c/lysozyme/CD3/CD20/CD34/ PD-L1) studies were performed in 7 DIG. Activating MAPK pathway alterations were identified in 4 (57%) cases: 3 had a BRAF mutation (V600E/V600D/V600-W604delinsDQTDG, at 8%-27% variant allele frequency) and 1 showed a TPM3-NRTK1 fusion. Copy number changes were infrequent and nonrecurrent. All tumors had at least 30% of cells morphologically and immunophenotypically consistent with microglial/macrophage lineage. Two subtotally resected tumors regrew; 1 was re-excised and received adjuvant treatment (chemotherapy/targeted therapy), with clinical response to targeted therapy only. Even with residual tumor, all patients are alive (median follow-up, 83 months; 19-139). This study further supports DIG as another MAPK pathway-driven neuroepithelial tumor, thus expanding potential treatment options for tumors not amenable to surgical cure, and suggests that DIG is a microglia/macrophage-rich neuroepithelial tumor with frequent low driver mutation allele frequencies.

KW - BRAF

KW - Desmoplastic infantile ganglioglioma (DIG)

KW - Glioma

KW - Molecular

KW - NTRK

KW - Pediatric

KW - TPM3

UR - http://www.scopus.com/inward/record.url?scp=85073644028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073644028&partnerID=8YFLogxK

U2 - 10.1093/jnen/nlz086

DO - 10.1093/jnen/nlz086

M3 - Article

C2 - 31562743

AN - SCOPUS:85073644028

VL - 78

SP - 1011

EP - 1021

JO - Journal of neuropathology and experimental neurology

JF - Journal of neuropathology and experimental neurology

SN - 0022-3069

IS - 11

ER -